Company Analysis
Sign in

Avalo Therapeutics, Inc. (AVTX)

Nasdaq: AVTX · Pharmaceutical Preparations · Wayne, PA · filing with the SEC since 2012
Full chart Alerts Compare
Grade2.6
◀ Past 1.6● Present 2.6▶ Future 3.3
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

The grade of Avalo Therapeutics, Inc.

Nine metrics read from its own filings, by tense
Headline grade
2.6/10
◀ Past1.625% of the headline
● Present2.635% of the headline
▶ Future3.340% of the headline

All three tenses have at least two readings, so the archetype blend applies as printed.

Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.

◀ Past

What did they actually do?

1.6/1025% of the headline grade · 2 of 3 filed, 1 estimated

Surviving crises

as filed
1.5/10

Has it survived what it has been through?

14 warning events since 2017; the latest 2024-05-23.

weight 22% of this tense · 15th percentile among 497 sector filers · read for itself

From the record

Avalo Therapeutics, Inc.'s filings since 2017 show 14 warning events of 2 kinds: a debt default or acceleration notice (8-K item 2.04, the latest 2023-07-21); a notice about its exchange listing (8-K item 3.01, 13 times, the latest 2024-05-23) (its current reports).

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Track record

as filed
2.3/10

What has it actually done, year after year?

-53.7% a year over 9 filed years; profitable in 1 of 9.

weight 45% of this tense · 23rd percentile among 323 sector filers · read for its customers

From the record

Avalo Therapeutics, Inc.'s 9 filed years say what it did: revenue went from $28 million in fiscal 2017 to $59 thousand in fiscal 2025, down 53.7% a year; it rose in 1 of 8 years; the deepest fall was 100% from fiscal 2017 to fiscal 2025; net income was positive in 1 of 9 of those years (its annual reports).

What it rests on

  • revenue growth over the filed span-53.7%bottom 3% of its family
  • the share of years revenue rosebottom 7% of its family
  • the share of filed years with a profittop 38% of its family
  • the deepest fall from a revenue peak99.8%bottom 21% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Shareholder treatment

SI estimate
0.5/10

How has it treated the people who own it?

SI estimate 0.5/10, confidence 35 of 100 (one part).

weight 33% of this tense · 5th percentile among 464 sector filers · read for its shareholders

SI estimate Inferred, not read as filed

Why it is an estimate
Read from one part only, the share count over the years, which ranks in the bottom 5% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
What the record cannot read
Fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income.
How it was reasoned
one part: the share count over the years, the one part on file, ranked among 464 in its family.
Confidence
35 of 100
What would change it
A filing that carries the missing parts replaces this estimate with the filed reading.

From the record

SI estimate, not a filed reading: Avalo Therapeutics, Inc.'s shareholder treatment is put at 0.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 5% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.

● Present

What are they doing right now?

2.6/1035% of the headline grade · 3 of 3 filed

Financial health

as filed
3.8/10

Is it financially healthy right now?

ROE -94%: lost 94¢ per shareholder dollar. Leverage 29%: owes 29¢ per asset dollar.

weight 45% of this tense · 38th percentile among 473 sector filers · read for itself

From the record

Return on equity: in the fiscal year ended 2025-12-31, Avalo Therapeutics, Inc. lost about 94 cents for every dollar of shareholders' money. Leverage: it owed about 29 cents per dollar of assets, and net share issuance: its share count grew 78.8% over the year (the filed statements).

What it rests on

  • what it owes per dollar of assetstop 45% of its family
  • return on equitybottom 33% of its family
  • the share count against the year beforebottom 27% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Industry position

as filed
0.3/10

How strong is its position in its industry?

bottom 3% of 315 in its family; net margin -132642.4%.

weight 22% of this tense · 3rd percentile among 315 sector filers · read for its customers

From the record

Avalo Therapeutics, Inc.'s standing among 315 graded names in its industry family: revenue of $59 thousand in fiscal 2025 ranks in the bottom 6% by size; a net margin of -132642.4% ranks in the bottom 2%; revenue growth of -85.2% a year over the last 3 filed years ranks in the bottom 2% (its annual reports).

What it rests on

  • revenue against the family$59,000bottom 6% of its family
  • net margin-132642.4%bottom 2% of its family
  • three-year revenue growth-85.2%bottom 2% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Leadership

as filed
2.4/10

What are the people in charge doing?

bottom 24% of 315 in its family for leadership; chief executive since 2022.

weight 33% of this tense · 24th percentile among 315 sector filers · read for its shareholders

From the record

Avalo Therapeutics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Neil, Garry Arthur (Chief Executive Officer, as filed), filing under that title since 2022-03-10, 4.7 years (bottom 45% of its family); the 15 officers and directors filing in the last fifteen months have been on the record a median of 2.4 years (bottom 10%); 13 officer or director changes were reported on Form 8-K since 2023-11-13, against the 15 people in charge now (bottom 16%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

What it rests on

  • officer and director changes on Form 8-K, against the people in charge13 in three years among 15 peoplebottom 16% of its family
  • the median years the people in charge have filed2.4 yearsbottom 10% of its family
  • the chief executive's years on the record4.7 yearsbottom 45% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

▶ Future

What are they set up to do next?

3.3/1040% of the headline grade · 3 of 3 filed

Room to expand

as filed
4.4/10

How much room does it have to grow?

bottom 44% of 273 in its family for room to expand.

weight 33% of this tense · 44th percentile among 273 sector filers · read for itself

From the record

Avalo Therapeutics, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $16 million against no long-term debt tagged leaves 13.6% of its assets as net cash, bottom 31% of its family; cash from operations less capital spending is -87216.9% of revenue (bottom 2%); research spending of 84888.1% of revenue (top 2%) (its annual report).

What it rests on

  • cash less debt against assets13.6%bottom 31% of its family
  • cash from operations less capital spending against revenue-87216.9%bottom 2% of its family
  • research spending against revenue84888.1%top 2% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Growth drivers

as filed
3.4/10

What could actually drive growth from here?

bottom 34% of 306 in its family for growth drivers.

weight 45% of this tense · 34th percentile among 306 sector filers · read for its customers

From the record

Avalo Therapeutics, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -85.2% a year over the last three filed years against -53.7% over all 9, slowing (bottom 19% of its family); the newest year grew -86.6% (bottom 5%); research spending grew 16.9% a year (top 27%); capital spending grew -28.7% a year (bottom 39%) (its annual reports). Avalo Therapeutics, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.

What it rests on

  • three-year growth against the whole span-31.5 points a yearbottom 19% of its family
  • the newest year's revenue growth-86.6%bottom 5% of its family
  • three-year growth of research spending16.9%top 27% of its family
  • three-year growth of capital spending-28.7%bottom 39% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

Expectations vs reality

as filed
1.7/10

Did its newest year beat what its own record pointed to?

bottom 17% of 233 in its family for expectations against reality.

weight 22% of this tense · 17th percentile among 233 sector filers · read for its shareholders

From the record

Avalo Therapeutics, Inc.'s newest year against its own record: revenue of $59 thousand in fiscal 2025 came in 14.5% below the $69 thousand its prior three years' pace pointed to (bottom 36% of its family); net income of $78 million against a prior three-year average of $36 million (bottom 13%); a net margin of a loss larger than its revenue against losses larger than its revenue before (bottom 1%) (its annual reports).

What it rests on

  • revenue against the prior three years' pace-14.5%bottom 36% of its family
  • net income against the prior three years' average-117%bottom 13% of its family
  • net margin against its prior averagedown more than 100 pointsbottom 1% of its family

A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.

The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made

SI Assistanton AVTX · research, not advice